Care for patients with solid tumors, hematologic malignancies, and benign hematologic disorders continues to evolve with the development of novel therapeutic agents and testing modalities, accumulation of clinical trial data, and ongoing revisions to expert guidelines.
Oncologists, hematologists, and other clinicians who participate in the care of patients with these disorders are challenged to stay current on the latest diagnosis, treatment, and management advances.
This intensive six-day course provides a comprehensive review of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions.
Primary emphasis will be placed upon the broad area of medical management within a multidisciplinary environment. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed.
This course will engage participants in lectures using an audience response system as well as interactive panels and case discussions.
Upon completion of this course participants will be able to:
- Incorporate new and emerging clinical data into expert recommended best practices for diagnosing, evaluating, and treating patients with breast cancer.
- Develop personalized treatment strategies for patients with lung, head and neck cancers, based on appropriate molecular testing and incorporating newly approved systemic therapies when appropriate.
- Choose from available systemic agents as part of multimodal treatment approaches for patients with gastrointestinal and neuroendocrine cancers based on current molecular testing and risk assessment methods.
- Develop treatment plans for prostate, testicular, renal, and bladder cancers that are tailored to individual patients’ risk factors and characteristics.
- Create evidence-based care plans for patientswith ovarian, cervical, endometrial, andtrophoblastic cancers that incorporate recentadvances in diagnosis and management.
- Update treatment practices in a wide range of lesscommon cancers, including brain tumors, thyroidcancer, melanoma, sarcoma, and mesothelioma,based on emerging clinical evidence and currentexpert recommendations.
- Develop evidence-based management plans forpatients with benign hematologic disorders,incorporating new diagnostic strategies and noveltherapies into current treatment paradigms.
- Create optimized supportive care and survivorship plans for patients with cancer that take into account recent guidelines and current expert recommendations.
- Course objectives are reviewed annually with the faculty for currency and relevance and refined as necessary by the Course Director and selected physician advisors.